|
|
News Breaks | | | | September 27, 2012 | | 07:27 EDT |  | BLRX | BioLineRx announces publication of Phase II EAGLE clinical trial
BioLineRx announced the publication of results from the Phase II EAGLE clinical trial for BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, showing that BL-1020 is safe and effective in improving schizophrenia, in addition to improving cognitive impairment associated with this condition. The findings, which were originally announced in September 2009, were published in the September 2012 issue of the Journal of Clinical Psychiatry. Results of the study shows that BL-1020 was significantly better than the placebo and comparable with Risperidone in both PANSS and CGI scores, which are widely recognized measures of severity and improvement in schizophrenia, the company said. | |
|
News For BLRX From The Last 14 Days Check below for free stories on BLRX the last two weeks. |
|
|
| May 17, 2013 | | 12:02 EDT |  | BLRX | BioLineRx enters at-the-market offering agreement with Stifel Nicolaus & Co.
 Subscribe for More Information | |
|
|
|
|
|
|
